Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for Allergic Bronchopulmonary Aspergillosis (ABPA) with Asthma
jRCT2080225350Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in allergic bronchopulmonary aspergillosis (ABPA) and asthma comparing Dupilumab with Placebo (2 arms). Started Aug 2020; status: completed.
02
Drugs
03
Conditions
allergic bronchopulmonary aspergillosis (ABPA)asthma
Beyond the preview
Go deeper on jRCT2080225350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225350.